What the Study Found (In Plain English)
Published in Pediatric research (2023), this phase iii randomized trial evaluating 68 human participants investigated: The effect of recombinant human GH (rhGH) in Chinese children with chronic kidney disease (CKD) is unclear. Key clinical takeaway: Daily rhGH for 52 weeks in children with CKD-induced growth retardation significantly improved HT-SDS and other growth parameters without compromising safety.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Pediatric research, 2023-07-15; N = 68; Rigor 82/100): Daily rhGH for 52 weeks in children with CKD-induced growth retardation significantly improved HT-SDS and other growth parameters without compromising safety.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.